ARANESP Drug Profile
✉ Email this page to a colleague
Summary for Tradename: ARANESP
| High Confidence Patents: | 2 |
| Applicants: | 1 |
| BLAs: | 1 |
| Drug Prices: | Drug price information for ARANESP |
| Recent Clinical Trials: | See clinical trials for ARANESP |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARANESP |
Recent Clinical Trials for ARANESP
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Region Stockholm | Phase 2 |
| H. Lee Moffitt Cancer Center and Research Institute | Phase 1/Phase 2 |
| Novartis Pharmaceuticals | Phase 1/Phase 2 |
Pharmacology for ARANESP
| Physiological Effect | Increased Erythroid Cell Production |
| Established Pharmacologic Class | Erythropoiesis-stimulating Agent |
| Chemical Structure | Erythropoietin |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for ARANESP Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for ARANESP Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2003-12-13 | Company disclosures |
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2024-05-15 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for ARANESP Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2039-02-26 | Patent claims search |
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2031-04-20 | Patent claims search |
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2036-04-01 | Patent claims search |
| Amgen Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | ⤷ Sign Up | 2032-02-15 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for ARANESP
Supplementary Protection Certificates for ARANESP
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 300075 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608 |
| 43/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
| PA2004015 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
| 132001900976055 | Italy | ⤷ Sign Up | AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/185/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19- 20-21-22-23-24-25-26-27-28-29-30, 20010608 |
| SPC/GB01/055 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
